CLINICAL_TRIALS
approval
· 2012-03-09
Clinical Trial Update: A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248
Summary
Pfizer's SU011248 (sunitinib) for gastrointestinal stromal tumor has been approved for marketing.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Gastrointestinal Neoplasm | Status: APPROVED_FOR_MARKETING